11/2/2026

speaker
Operator
Conference Call Operator

Hello everyone, thank you for joining us and welcome to the BioMarin third quarter 2026 conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the call over to BioMarin's Head of Investor Relations, Tracy McCarty. Please go ahead.

speaker
Tracy McCarty
Head of Investor Relations

Thank you, Operator. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of Biomarin Pharmaceutical Inc., including expectations regarding Biomarin's financial performance, commercial products, and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of Biomarin's product programs, actions of regulatory authorities, availability of capital, Future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10Q, 10K, and 8K reports. In addition, we will use non-GAAP financial measures as defined in Regulation G during the call today. These non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to, financial measures prepared in accordance with U.S. GAAP. and you can find the related reconciliations to US GAAP in the earnings release and earnings presentation, both of which are available in the investor relations section of our website. Please note that our commentary on today's call will focus on non-GAAP financial measures unless otherwise indicated. Beginning on slide three and introducing Biomarin's management team joining today's call, Alexander Hardy, Chief Executive Officer, Cristin Hubbard, Chief Commercial Officer Greg Friberg, Chief R&D Officer, and Brian Mueller, Chief Financial Officer. I will now turn the call over to Alexander to provide our quarterly highlights. Alexander?

speaker
Alexander Hardy
Chief Executive Officer

Thank you, Tracy, and thank you all for joining us today. Starting on slide five, strong demand across our diversified portfolio of innovative therapies drove 32% year-over-year growth in the third quarter, surpassing $1 billion and many more. Also last week, we announced the addition of a new investigational Fabray asset to our clinical portfolio. Recently renamed BMN450, the fourth new asset added to our pipeline in 2026. This highlights the focused and deliberate expansion of Biomarin's clinical stage pipeline. BMN450 has the potential Thank you for joining us. They totaled more than $200 million in combined revenues in the quarter, while at the same time, the pace of the Amicus cost synergies realization exceeded our expectations. We are energized by the addition of our Amicus colleagues, and we're working together to expand the reach of both Gallifold and Pompility and Opfolder, bringing these therapies to more patients around the world. I am also pleased with the continued global expansion of VoxOgo as the number of children treated increased by 17% worldwide. Building on this momentum, we are pleased to share that May 30th, 2027 is the PDUFA date for VoxOgo for the treatment of hypochondriplasia, the first targeted therapy to potentially be approved for the indication and a potential and the seventh first in disease medicine for Biomarin. The team is well prepared for strong launches in hypochondriplasia in the US and Europe, and we anticipate both regions will benefit from our global leadership in skeletal conditions. Before I turn the call over to Cristin, I want to say a few words about the work we are doing to expand our pipeline, including the most recent addition to our clinical portfolio. BMN 450 is a phase 1-2 compound that builds on our Gallifold experience and has the potential to expand the therapeutic reach to those with Fabry whose variants are not amenable to Gallifold. The Amen 450 is a strategically compelling addition to our metabolic conditions BU, addressing treatment burden and a priority unmet need with a differentiated, long-acting, subcutaneous profile. It also reflects our growing commitment to the Fabry community, building on the Amherst acquisition, as well as the expertise and relationships established with Gallifold. In summary, we delivered strong financial results in the third quarter and made meaningful progress across every part of our business. In a moment, Brian will speak to some expected order timing dynamics and geopolitical headwinds that we are observing, resulting in today's updated guidance. In 2026, we have delivered on the strategic expansion of our innovative pipeline, including the addition of BMN 450, BMN 440 for hypophosphatasia, BMN 430 for a new syndrome, and BMN 820 for FSGS. Our business development execution, having delivered five deals in two years, demonstrates our capabilities across the value chain as a rare disease leader operating at scale. Our commercial portfolio is now more diversified and more resilient following the successful acquisition of Amicus, as well as our pipeline with the more recently acquired earlier stage assets. We look ahead with enthusiasm for what's to come as we advance the next wave of therapies from our clinical stage pipeline and to reporting on a number of key updates in 2027. Combined with the strength of our more diversified commercial portfolio, we are confident in our ability to create lasting value for patients and all of our stakeholders. And we look forward to updating you on our progress. I will now turn the call over to Cristin for more detail on our commercial performance. Cristin.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API